Belsomra is owned by Merck Sharp Dohme.
Belsomra contains Suvorexant.
Belsomra has a total of 2 drug patents out of which 0 drug patents have expired.
Belsomra was authorised for market use on 13 August, 2014.
Belsomra is available in tablet;oral dosage forms.
Belsomra can be used as treatment of insomnia.
The generics of Belsomra are possible to be released after 29 May, 2033.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7951797||MERCK SHARP DOHME||Substituted diazepan orexin receptor antagonists|| |
(6 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10098892||MERCK SHARP DOHME||Solid dosage formulations of an orexin receptor antagonist|| |
(10 years from now)
|M||Jan 29, 2023|
Market Authorisation Date: 13 August, 2014
Treatment: Treatment of insomnia
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic